Zacks.com on MSN18h
FDA Begins Review of Alnylam's sNDA for Expanded Amvuttra UseAlnylam Pharmaceuticals ALNY announced that the FDA has accepted its supplemental new drug application (sNDA) seeking the ...
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) – Investment analysts at Zacks Research increased their FY2024 ...
The FDA has accepted Alnylam’s supplemental New Drug Application for Amvuttra on the heels of BridgeBio’s Attruby nod, ...
Scotiabank analyst Greg Harrison maintained a Buy rating on Alnylam Pharma (ALNY – Research Report) today and set a price target of $310.00.
In a report released today, Liisa Bayko from Evercore ISI maintained a Buy rating on Alnylam Pharma (ALNY – Research Report), with a price ...
BridgeBio Pharma snagged FDA approval for its rival to Pfizer's heart disease treatment, Vyndaqel. BridgeBio stock catapulted ...
Delving into the details, we found 5% of traders were bullish, while 84% showed bearish tendencies. Out of all the trades we spotted, 14 were puts, with a value of $931,387, and 5 were calls, valued ...
DelveInsight’s “Hemophilia B Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding ...
The presumptive new CDC director, Dave Weldon, is a known vaccine safety skeptic. In contrast, the FDA choice — Johns Hopkins ...
Alnylam Pharmaceuticals has revealed new interim data from its Phase I trial of nucresiran, a ribonucleic acid interference ...
--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the presentation of new results from its Phase 1 study of nucresiran ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback